General principles of therapy of pyogenic meningitis
- PMID: 2277194
General principles of therapy of pyogenic meningitis
Abstract
In bacterial meningitis, several pharmacodynamic factors determine therapeutic success-when defined as sterilization of the CSF: (1) Local host defense deficits in the CNS require the use of bactericidal antibiotics to sterilize the CSF. (2) CSF antibiotic concentrations that are at least 10-fold above the MBC are necessary for maximal bactericidal activity. Protein binding, low pH, and slow bacterial growth rates are among the factors that may explain the high antibiotic concentrations necessary in vivo. (3) High CSF peak concentrations that lead to rapid bacterial killing appear more important than prolonged suprainhibitory concentrations, probably because very low residual levels in the CSF prevent bacterial regrowth, even during relatively long dosing intervals. (4) Penetration of antibiotics into the CSF is significantly impaired by the blood-brain barrier and thus, very high serum levels are necessary to achieve the CSF concentrations required for optimal bactericidal activity. Beyond these principles, recent data suggests that rapid lytic killing of bacteria in the CSF may have harmful effects on the brain because of the release of biologically active products from the lysed bacteria. Since rapid CSF sterilization remains a key therapeutic goal, the harmful consequences of bacterial lysis present a major challenge in the therapy of bacterial meningitis. Currently, dexamethasone represents that only clinically beneficial approach to reduce the harmful effects of bacterial lysis, and novel approaches are required to improve the outcome of this serious infection.
Similar articles
-
Pharmacodynamics of antibiotics in experimental bacterial meningitis--two sides to rapid bacterial killing in the cerebrospinal fluid.Scand J Infect Dis Suppl. 1990;74:173-8. Scand J Infect Dis Suppl. 1990. PMID: 2097706 Review.
-
Gram-negative bacillary meningitis. New therapy and changing concepts.Arch Intern Med. 1982 May;142(5):939-40. Arch Intern Med. 1982. PMID: 6211153
-
Pharmacodynamics of antibiotics in the therapy of meningitis: infection model observations.J Antimicrob Chemother. 1993 May;31 Suppl D:61-70. doi: 10.1093/jac/31.suppl_d.61. J Antimicrob Chemother. 1993. PMID: 8335525 Review.
-
The influence of dosing schedules and cerebrospinal fluid bactericidal activity on the therapy of bacterial meningitis.J Antimicrob Chemother. 1985 Jan;15 Suppl A:303-12. doi: 10.1093/jac/15.suppl_a.303. J Antimicrob Chemother. 1985. PMID: 3980333
-
Current concepts in clinical therapeutics: bacterial meningitis in infants and children.Clin Pharm. 1986 Oct;5(10):798-809. Clin Pharm. 1986. PMID: 3536267 Review.
Cited by
-
Bacterial meningitis. Practical guidelines for management.Drugs. 1995 Nov;50(5):838-53. doi: 10.2165/00003495-199550050-00005. Drugs. 1995. PMID: 8586029 Review.
-
Cefpirome clinical pharmacokinetics.Clin Pharmacokinet. 1993 Oct;25(4):263-73. doi: 10.2165/00003088-199325040-00002. Clin Pharmacokinet. 1993. PMID: 8261711 Review.
-
Bacterial meningitis: current controversies in approaches to treatment.CNS Drugs. 2001;15(12):909-19. doi: 10.2165/00023210-200115120-00001. CNS Drugs. 2001. PMID: 11735611 Review.
-
Diagnosis and treatment of bacterial meningitis.Arch Dis Child. 2003 Jul;88(7):615-20. doi: 10.1136/adc.88.7.615. Arch Dis Child. 2003. PMID: 12818910 Free PMC article. Review.
-
Use of ampicillin-sulbactam for treatment of experimental meningitis caused by a beta-lactamase-producing strain of Escherichia coli K-1.Antimicrob Agents Chemother. 1991 Oct;35(10):2037-41. doi: 10.1128/AAC.35.10.2037. Antimicrob Agents Chemother. 1991. PMID: 1759824 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials